<qa>  What is the purpose of the project?The aim of the project is to investigate the use of raloxifene a new form of estrogen as a treatment for schizophrenia in postmenopausal women. Raloxifene is a selective estrogen receptor modulator SERM which means that it can affect the central nervous system effects of estrogen eg: improving emotional symptoms, memory, information processing and concentration, without adversely affecting reproductive tissue organs such as breast, uterus and ovaries.We are conducting a double blind placebo controlled 3 month duration study comparing the psychotic symptom response between three groups of postmenopausal women with schizophrenia. One group will receive standard antipsychotic medication plus 60mg Raloxifene, the second group receives standard antipsychotic medication plus Hormone Therapyestradiol 2mg oral per day dyhydroprogesterone 10mg oral per day and the third group receives standard antipsychotic medication plus oral placebo. Hypothesis 1: That the women receiving adjunctive raloxifene or HT would have a quicker recovery from psychotic symptoms, as measured on the rating scales, compared with the women receiving adjunctive placebo.Hypothesis 2: That the Raloxifene group would have better cognitive improvement than the other two groups. 